The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science., Dec;330(6010):1551-7 (2010)
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
J. Infect. Dis., Jul;198(2):234-40 (2008)
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
J. Infect. Dis., Apr;191(7):1155-63 (2005)
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
AIDS., Jul;18(11):1529-37 (2004)
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Pharmacotherapy., Nov;23(11):1432-40 (2003)